Drugs / Susu Xiao'er Zhike Granules
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04457011 | Sep 2020 → Feb 2022 | — | Tasly Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06773117 | Sep 2025 → May 2027 expected | — | Tasly Pharmaceutical Group Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Susu Xiao'er Zhike Granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04457011 ↗ |
| Known as | Susu | “Susu used to be a clinical experienced Chinese herb formula for treating acute cough caused by common cold.” NCT04457011 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Susu used to be a clinical experienced Chinese herb formula for treating acute cough caused by common cold.” NCT04457011 ↗ |